JBC:上海药物研究所揭示证实了cofilin异常O-GlcNAc糖基化促进乳腺癌转移

2013-11-13 佚名 生物通

 来自中科院上海药物研究所的研究人员在新研究中证实,肌动蛋白结合蛋白Cofilin发生O-GlcNAc 糖基化(O-GlcNAcylation)促进了乳腺癌细胞侵袭。相关研究论文发表在11月8日的《生物化学杂志》(JBC)上。中国工程院院士、上海药物研究所所长丁健(Jian Ding)研究员和副所长耿美玉(Meiyu Geng)研究员是这篇论文的共同通讯作者。丁院士的主要研究方向包括肿瘤

 
来自中科院上海药物研究所的研究人员在新研究中证实,肌动蛋白结合蛋白Cofilin发生O-GlcNAc 糖基化(O-GlcNAcylation)促进了乳腺癌细胞侵袭。相关研究论文发表在11月8日的《生物化学杂志》(JBC)上。

中国工程院院士、上海药物研究所所长丁健(Jian Ding)研究员和副所长耿美玉(Meiyu Geng)研究员是这篇论文的共同通讯作者。丁院士的主要研究方向包括肿瘤新生血管生长抑制剂;激酶抑制剂;PI3K-mTOR抑制剂;抗肿瘤转移研究;表观遗传;肿瘤生物标志物。耿美玉课题组研究方向包括受体酪氨酸激酶c-Met、ALK、FGFR抑制剂;肿瘤代谢;微环境、EMT与肿瘤转移;肿瘤生物标志物。

乳腺癌是全球女性中发病率及致死率最高的恶性肿瘤,每年有将近130万女性患上乳腺癌,并且有超过40万女性因为乳腺癌的转移复发而死亡。探索发现乳腺癌侵袭、转移的分子机制,不仅可以预测乳腺癌术后复发转移的高危因素,而且还可能指导乳腺癌的个体化治疗及为靶向治疗药物的开发提供理论依据。

蛋白质是生命活动的执行体,细胞内许多蛋白质的功能是通过动态的蛋白质翻译后修饰来实现的。在真核动物细胞中有20多种蛋白质翻译后修饰过程,常见的有泛素化、磷酸化、糖基化、脂基化、甲基化和乙酰化等。O-GlcNAc 糖基化修饰作为一种特殊的蛋白质翻译后修饰形式,是许多细胞过程例如信号转导、转录和蛋白酶体降解的重要调控因子,参与调控了增殖、分化、粘附和凋亡等多种生物学功能。

Cofilin是普遍存在于真核细胞的一种肌动蛋白结合蛋白。Cofilin的基本功能是在细胞内结合和解聚F-肌动蛋白(F-actin),其活性可通过磷酸化、去磷酸化、磷酸肌醇、pH改变等进行调节。Cofilin介导了细胞内的信号途径,从而调节肌动蛋白骨架的重组,对细胞迁移起到重要作用,并且与癌症的转移密切相关。在多种癌症细胞中,Cofilin受到复杂的调控。


在这篇文章中,研究人员证实O-GlcNAc糖基转移酶(O-GlcNAc transferase, OGT)可使cofilin O-GlcNAc 糖基化,cofilin介导了OGT相关的细胞运动改变。Cofilin的Ser108位点O-GlcNAc 糖基化是在细胞侵袭过程中,cofilin在乳腺癌细胞前缘侵袭伪足(invadopodia)中发挥适当功能的必要条件。Cofilin不发生O-GlcNAc 糖基化修饰会导致侵袭伪足失去稳定,损害癌细胞侵袭。

新研究揭示了cofilin功能的一条翻译后修饰机制,证实了cofilin异常O-GlcNAc糖基化对于癌症转移具有重要的影响。

原文出处:

Huang X, Pan Q, Sun D, Chen W, Shen A, Huang M, Ding J, Geng M.
O-GlcNAcylation of cofilin promotes breast cancer cell invasion.J Biol Chem. 2013 Nov 8.【原文下载】


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2036399, encodeId=9fc1203639945, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Apr 19 00:10:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801004, encodeId=2b411801004b1, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Dec 04 02:10:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318279, encodeId=5e6713182e959, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Nov 15 04:10:00 CST 2013, time=2013-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590247, encodeId=4405159024e57, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Nov 15 04:10:00 CST 2013, time=2013-11-15, status=1, ipAttribution=)]
    2014-04-19 lily1616
  2. [GetPortalCommentsPageByObjectIdResponse(id=2036399, encodeId=9fc1203639945, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Apr 19 00:10:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801004, encodeId=2b411801004b1, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Dec 04 02:10:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318279, encodeId=5e6713182e959, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Nov 15 04:10:00 CST 2013, time=2013-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590247, encodeId=4405159024e57, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Nov 15 04:10:00 CST 2013, time=2013-11-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2036399, encodeId=9fc1203639945, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Apr 19 00:10:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801004, encodeId=2b411801004b1, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Dec 04 02:10:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318279, encodeId=5e6713182e959, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Nov 15 04:10:00 CST 2013, time=2013-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590247, encodeId=4405159024e57, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Nov 15 04:10:00 CST 2013, time=2013-11-15, status=1, ipAttribution=)]
    2013-11-15 lfyang
  4. [GetPortalCommentsPageByObjectIdResponse(id=2036399, encodeId=9fc1203639945, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Apr 19 00:10:00 CST 2014, time=2014-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801004, encodeId=2b411801004b1, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Dec 04 02:10:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318279, encodeId=5e6713182e959, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Nov 15 04:10:00 CST 2013, time=2013-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590247, encodeId=4405159024e57, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Fri Nov 15 04:10:00 CST 2013, time=2013-11-15, status=1, ipAttribution=)]